PhD position: Sphingolipid-dependent modulation of the TLR and IL-1/TIR signaling and its role for antigen-specific cytotoxic T lymphocyte anti-cancerogenic activity
“Sphingolipid-dependent modulation of the TLR and IL-1/TIR signaling and its role for antigen-specific cytotoxic T lymphocyte anti-cancerogenic activity”
in the laboratory of Prof. Dr. Heinfried Radeke
Based on previous studies in our group showing that S1P is affecting TLR-induced IL-12 expression in dendritic cells and IL-33-dependent functions of CD8 cytotoxic lymphocytes we concluded that the TLR / TIR pathway is exclusively sensitive to sphingolipid receptor and enzyme dependent modulation. Because both, IL-12 and CD8, are the most prominent determinants of immune defense against cancerogenesis and established tumors, the PhD project will focus on the characterization of the antitumor regulatory circuits. Recently, we already established different types of specific in vitro anticancer immune assays including 3D cultures of cancer cells (spheroids) as well as in vivo inflammation-cancer models. The applicant should have strong immunological and protein biochemical background.
The Else Kröner-Fresenius Research Training Group “Eicosanoid and sphingolipid pathways in inflammation, cancer and vascular diseases” is an international research training group at the Goethe University Frankfurt and the Karolinska Institute in Stockholm and is funded by the Else Kröner-Fresenius-Stiftung. The focus of this research training group is on intensifying the understanding of the physiological and pathophysiological roles of eicosanoids and sphingolipids in inflammatory processes, cancer and vascular diseases. The Else Kröner-Fresenius Research Training Group is embedded in the Graduate Centre FIRST (Frankfurt International Research School for Translational Biomedicine) of the Goethe Graduate Academy (GRADE). FIRST provides postgraduate education in all aspects of translationals biomedicine with a focus on the processes involved in drug research and development.
Candidates should already possess a first class MSc (biology, pharmacy or related discipline) or an MD degree. Applications consisting of a cover letter indicating the motivation for this project as well as a full curriculum vitae containing a brief summary of previous research projects, together with copies of all relevant university certificates should be sent by email to Dr. Brigitte Held (firstname.lastname@example.org). Hard copy version can be to the postal address: Dr. Brigitte Held, Institut für Pharmazeutische Chemie, Goethe Universität Frankfurt, Max-von-Laue-Str. 9, D - 60438 Frankfurt. Incomplete applications will not be considered.
The application deadline is May 28nd, 2016. Short listed applications will be required to attend a selection workshop in Frankfurt.
Stipends will be paid according to the rules of the Deutsche Forschungsgemeinschaft.
For further information on the projects as well as FIRST, please visit: www.first-gradschool.de
Bitte beziehen Sie sich bei Ihrer Bewerbung auf jobvector
Institut für Pharmazeutische Chemie
Goethe Universität Frankfurt
D - 60438 Frankfurt.
Details der Stellenanzeige
Über Johann Wolfgang Goethe Universität Frankfurt am Main
The graduate centre FIRST is a unique organization of the Johann Wolfgang Goethe University of Frankfurt, the Georg Speyer Haus (GSH) and the Paul Ehrlich Institute (PEI) in Langen. At Frankfurt University, groups within the faculties Medicine (FB16) and Biochemistry, Chemistry and Pharmaceutical Sciences (FB14) that address different aspects of drug research from basics up to clinical...Mehr über die Johann Wolfgang Goethe Universität Frankfurt am Main